Dynamic path analysis - a useful tool to investigate mediation processes in clinical survival trials

被引:15
|
作者
Strohmaier, Susanne [1 ]
Roysland, Kjetil [1 ]
Hoff, Rune [1 ]
Borgan, Ornulf [2 ]
Pedersen, Terje R. [3 ]
Aalen, Odd O. [1 ]
机构
[1] Univ Oslo, Oslo Ctr Biostat & Epidemiol, Dept Biostat, N-0317 Oslo, Norway
[2] Univ Oslo, Dept Math, N-0317 Oslo, Norway
[3] Univ Oslo, Ulleval Hosp, N-0317 Oslo, Norway
关键词
additive hazard regression; directed acyclic graphs; direct effect; IDEAL study; indirect effect; mediation analysis; survival analysis; MYOCARDIAL-INFARCTION; APOLIPOPROTEIN-B; END-POINTS; CHOLESTEROL; EVENTS; RISK;
D O I
10.1002/sim.6598
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
When it comes to clinical survival trials, regulatory restrictions usually require the application of methods that solely utilize baseline covariates and the intention-to-treat principle. Thereby, much potentially useful information is lost, as collection of time-to-event data often goes hand in hand with collection of information on biomarkers and other internal time-dependent covariates. However, there are tools to incorporate information from repeated measurements in a useful manner that can help to shed more light on the underlying treatment mechanisms. We consider dynamic path analysis, a model for mediation analysis in the presence of a time-to-event outcome and time-dependent covariates to investigate direct and indirect effects in a study of different lipid-lowering treatments in patients with previous myocardial infarctions. Further, we address the question whether survival in itself may produce associations between the treatment and the mediator in dynamic path analysis and give an argument that because of linearity of the assumed additive hazard model, this is not the case. We further elaborate on our view that, when studying mediation, we are actually dealing with underlying processes rather than single variables measured only once during the study period. This becomes apparent in results from various models applied to the study of lipid-lowering treatments as well as our additionally conducted simulation study, where we clearly observe that discarding information on repeated measurements can lead to potentially erroneous conclusions. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:3866 / 3887
页数:22
相关论文
共 50 条
  • [41] Bayesian survival analysis in clinical trials: What methods are used in practice?
    Brard, Caroline
    Le Teuff, Gwenael
    Le Deley, Marie-Cecile
    Hampson, Lisa V.
    CLINICAL TRIALS, 2017, 14 (01) : 78 - 87
  • [42] Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques
    Vandenberghe, Sjouke
    Duchateau, Luc
    Slaets, Leen
    Bogaerts, Jan
    Vansteelandt, Stijn
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2018, 27 (11) : 3367 - 3385
  • [43] A WINDOWS SOFTWARE APPLICATION TO ASSESS ARTERIAL DYNAMIC BEHAVIOR - A USEFUL TOOL IN LABORATORY AND NONINVASIVE CLINICAL RESEARCH
    RISK, MR
    ARMENTANO, RL
    BARRA, JG
    PERAZZO, CA
    PICHEL, RH
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, : A4 - A4
  • [44] Spatiotemporal Fluctuation Analysis: A Powerful Tool for the Future Nanoscopy of Dynamic Molecular Processes
    Cardarelli, Francesco
    Gratton, Enrico
    Beltram, Fabio
    Di Rienzo, Carmine
    BIOPHYSICAL JOURNAL, 2017, 112 (03) : 149A - 149A
  • [45] Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: An useful tool for diagnosis and assessment of outcome in clinical trials
    Caillot, Denis
    Latrabe, Valerie
    Thiebaut, Anne
    Herbrecht, Raoul
    De Botton, Stephane
    Pigneux, Arnaud
    Monchecourt, Francoise
    Mahi, Lamine
    Alfandari, Serge
    Couaillier, Jean-Francois
    EUROPEAN JOURNAL OF RADIOLOGY, 2010, 74 (03) : E173 - E176
  • [46] Use of the likelihood reduction factor in a path analysis framework to quantify surrogacy in clinical trials
    Bloore, Katherine
    Song, Yang
    Cabral, Howard
    Massaro, Joseph
    LaValley, Michael
    STATISTICS IN MEDICINE, 2021, 40 (28) : 6373 - 6386
  • [47] Functional analysis of Microcystis vertical migration:: A dynamic model as a prospecting tool I -: Processes analysis
    Rabouille, S
    Salençon, MJ
    Thébault, JM
    ECOLOGICAL MODELLING, 2005, 188 (2-4) : 386 - 403
  • [48] Comment on Propofol and survival: an updated meta-analysis of randomized clinical trials
    Glass, Adam
    McCall, Philip
    Shelley, Ben
    CRITICAL CARE, 2023, 27 (01)
  • [49] Comment to: Propofol and survival: an updated meta-analysis of randomized clinical trials
    Benavides-Zora, David
    Arias-Botero, Jose Hugo
    CRITICAL CARE, 2023, 27 (01)
  • [50] Comment to: Propofol and survival: an updated meta-analysis of randomized clinical trials
    David Benavides-Zora
    Jose Hugo Arias-Botero
    Critical Care, 27